(:NVH*CA)
Business Focus: N/A
Nov 18, 2020 07:00 am ET
Novoheart Holdings Inc. has Closed its Going-Private Transaction
Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH) is pleased to announce that the previously announced acquisition by Novomed Limited (the “Purchaser”), a company beneficially owned by entities controlled by Prof. Ronald Li, Dr. Yu...
Nov 16, 2020 02:53 pm ET
Novoheart Holdings Inc. Receives Final Order Approving Going-Private Transaction
Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH) is pleased to announce that the previously announced acquisition by Novomed Limited (the “Purchaser”), a company beneficially owned by entities controlled by Prof. Ronald Li, Dr. Yu...
Nov 10, 2020 08:30 pm ET
Novoheart Holdings Inc. Receives Securityholder Approval of Going-Private Transaction
Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH) is pleased to announce that the previously announced acquisition by Novomed Limited (the “Purchaser”), a company beneficially owned by entities controlled by Prof. Ronald Li, Dr. Yu...
Sep 16, 2020 02:00 am ET
Novoheart Holdings Inc. Enters into Definitive Agreements for Going-Private Transaction
Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH) announces that it has entered into a definitive arrangement agreement (the “Arrangement Agreement”) with Novomed Limited (the “Purchaser”), a company controlled by Prof. Ronald Li,...
Aug 31, 2020 06:00 am ET
Novoheart Holdings Inc. Reports Second Quarter 2020 Financial Results
Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and six months ended June 30, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International...
May 19, 2020 06:00 am ET
Novoheart Holdings Inc. Reports First Quarter 2020 Financial Results and Announces AGM Results
Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three months ended March 31, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial...
Mar 11, 2020 06:00 pm ET
Novoheart Holdings Inc. Reports Second Quarter and Fiscal 2019 Financial Results
Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and six months ended December 31, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International...
Feb 20, 2020 09:30 am ET
Novoheart Named 2020 Venture 50 Company, Ranked Among Year’s Top Performing Stocks in Life Sciences
Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, is pleased to announce that it has been named a 2020 Venture 50 Company, ranked among the TSX Venture Exchange’s top 50 best performing...
Jan 21, 2020 03:00 am ET
Novoheart Contracts with Global Pharma to Develop Novel Microplate for High Throughput Drug Screening Using Engineered Human Heart Tissue Strips
Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, is pleased to announce the completion of a research and development contract sponsored by a top 10 global pharma. The contract deliverables...
Jan 07, 2020 03:00 am ET
Continued Success of Novoheart to Receive R&D Grants: Innovation Technology Fund for Developing Smart Cardiac Screening Technologies
Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, is pleased to announce that its wholly owned subsidiary Novoheart Limited has been awarded a further grant from the Innovation and Technology...
Dec 16, 2019 03:05 am ET
Novoheart Licenses Harvard Technology to Develop Next-Generation Human Heart-in-a-Jar
Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotech company that invented and commercialized the world’s first and only “human heart-in-a-jar” model for drug discovery and development, is pleased to announce...
Nov 29, 2019 09:00 pm ET
Novoheart Announces Change of Fiscal Year-End and Grants Stock Options
Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announced that it is changing its fiscal year-end to December 31, from its current fiscal year-end of June 30. The notice for the year-end change required under National...
Nov 29, 2019 08:00 pm ET
Novoheart Provides Corporate Update
Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announced today that Joseph Leung resigned as Chief Financial Officer and Corporate Secretary of the Company effective immediately. Ronald Li, Chief Executive Officer,...
Nov 26, 2019 12:02 am ET
Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca
Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, is pleased to announce a collaboration with global biopharmaceutical company AstraZeneca, in an effort to develop the world’s first...
Nov 19, 2019 07:00 pm ET
Novoheart Holdings Inc. Reports First Quarter 2020 Financial Results
Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three months ended September 30, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International...
Oct 08, 2019 11:00 pm ET
Novoheart Grants Stock Options
Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announces that it has granted incentive stock options to purchase an aggregate of 1,150,000 common shares of the Company (the “Options”) to non-executive directors of the...
Sep 09, 2019 12:05 am ET
Two new Pfizer-coauthored studies validate Novoheart’s pioneering human bioengineered heart tissues and chambers for improving drug development
Lab-grown heart tissues and chambers from Novoheart, (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, demonstrate advanced capabilities for drug screening as well as disease modeling which can lead to...
Sep 05, 2019 07:00 am ET
Novoheart Holdings Inc. Reports Fourth Quarter and Fiscal 2019 Financial Results
Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and twelve months ended June 30, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International...
Jun 29, 2019 12:32 am ET
Novoheart Holdings Inc. Completes Acquisition of Xellera Therapeutics
Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) is pleased to announce that it has completed its previously announced acquisition (the “Acquisition”) of all of the shares of Xellera Therapeutics Limited (“XT”). As...
Jun 17, 2019 03:00 am ET
Novoheart Announces Appointment of New Chief Financial Officer
Novoheart Holdings Inc. (“Novoheart” or the “Company”) announced the appointment of Joseph Leung (“Joseph”) as its new Chief Financial Officer (“CFO”) and Corporate Secretary. Joseph will be replacing Dr. Camie Chan, who has been serving as the...
Jun 06, 2019 04:11 pm ET
IIROC Trading Resumption - NVH
VANCOUVER, June 6, 2019 /CNW/ - Trading resumes in:
May 28, 2019 10:47 am ET
Novoheart to Acquire Xellera Therapeutics
Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announced that effective on May 27, 2019, it has entered into a definitive non-arm’s length agreement to acquire (the “Acquisition”) all of the shares of Xellera...
May 27, 2019 09:27 am ET
IIROC Trading Halt - NVH
VANCOUVER, May 27, 2019 /CNW/ - The following issues have been halted by IIROC:
May 17, 2019 05:00 pm ET
Novoheart Holdings Inc. Reports Third Quarter 2019 Financial Results and Stock Option Grants
Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and nine months ended March 31, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International...
Apr 11, 2019 02:45 am ET
Novoheart Announces Revolving Credit Facility
Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announces that its subsidiary, Novoheart Limited (Hong Kong), has entered into a demand revolving credit facility for up to HKD$ 30 million (approximately $5 million) (the...
Mar 06, 2019 08:00 pm ET
Novoheart Grants Stock Options
Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announces that it has granted incentive stock options to purchase an aggregate of 1,233,251 common shares of the Company (the “Options”) to directors and employees of the...
Mar 01, 2019 07:50 pm ET
Novoheart Holdings Inc. Reports Second Quarter 2019 Financial Results and Announces AGM Results
Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and six months ended December 31, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International...
Feb 08, 2019 05:43 pm ET
Novoheart Grants Stock Options and RSUs
Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announces that it has granted incentive stock options to purchase an aggregate of 420,613 common shares of the Company (the “Options”) and 2,355,000 restricted share units...
Jan 07, 2019 08:00 am ET
Novoheart Provides Corporate Update
Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announced today that Iris Lo has tendered her resignation as Chief Financial Officer and Corporate Secretary of the Company effective January 4, 2019. The appointment of...
Nov 22, 2018 08:21 pm ET
Novoheart Holdings Inc. Reports First Quarter 2019 Financial Results
Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three months ended September 30, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International...
Oct 31, 2018 04:42 am ET
Novoheart to Generate USD $1.7m From Strategic Partnership to Build Good Manufacturing Practice Facility to Create Clinical-Grade Human Stem Cell Libraries
Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, is pleased to announce that it has entered into a service agreement with Xellera Therapeutics Limited, representing Phase 1 of an intended...
Sep 24, 2018 03:05 am ET
Novoheart Recruits Notable Pharma Industry Executive, Bernard Fermini, Ph.D. as Chief R&D Officer
Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, announced today that it has appointed Bernard Fermini, Ph.D. as Chief Research Development Officer. Dr. Fermini has been a leading figure...
Aug 22, 2018 10:10 pm ET
Novoheart Holdings Inc. Reports Fourth Quarter and Fiscal 2018 Financial Results
Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and twelve months ended June 30, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International...
Aug 01, 2018 03:05 am ET
Novoheart Appoints Biotech Industry Specialist as New Senior Vice President to Lead Commercial Development
Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, announced today that it has hired Bill A. Williams, Ph.D. as Senior Vice President, Commercial Operations. With over 20 years of experience...
Jun 25, 2018 03:05 am ET
Novoheart Announces Presentation at the International Society for Stem Cell Research Annual Meeting
Novoheart (“Novoheart” or the “Company”) (TSX-V:NVH) (FWB:3NH) is pleased to announce a presentation was delivered on June 22nd, 2018, entitled “Modeling Cardiac Dysfunction of Friedreich’s Ataxia Using Ventricular Sheets, Tissues and Chambers...
Jun 13, 2018 03:00 am ET
Novoheart Wins Coveted 2018 MedTech Breakthrough Award
Novoheart (“Novoheart” or the “Company”) (TSXV:NVH) (FWB:3NH), a global stem cell biotechnology company, announced today that its MyHeart™ platform has been selected as 2018’s “Best New Technology Solution – Drug Development” by MedTech...
Jun 06, 2018 05:20 am ET
Novoheart Receives C$400,000 in Research Funding from the Innovation and Technology Commission of Hong Kong
Novoheart (“Novoheart” or the “Company”) (TSXV:NVH) (FWB:3NH), a global stem cell biotechnology company, is pleased to announce that its wholly owned subsidiary, Novoheart Limited, has been awarded a non-dilutional government grant of C$400,000...
May 31, 2018 03:00 am ET
Novoheart Becomes Member of International Consortium Advancing Cardiac Safety in Drug Development
Novoheart (“Novoheart” or the “Company”) (TSX-V:NVH) (FWB:3NH), a global stem cell biotechnology company, announced today that it has become a member of the Cardiac Safety Technical Committee of the Health and Environmental Sciences Institute...
May 11, 2018 07:20 pm ET
Novoheart Holdings Inc. Reports Third Quarter 2018 Financial Results
Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and nine months ended March 31, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International...
May 02, 2018 03:05 am ET
Novoheart to Debut New, State-of-the-art ‘Human Heart-in-a-Jar 2.0’ Technology at the 2018 International Society for Stem Cell Research (ISSCR) Annual Meeting
ISSCR Meeting in Melbourne to host over 4,000 attendees including notable scientists, innovators, industry representatives and mediaNovoheart’s proprietary ‘Human heart-in-a-jar 2.0’ now enhanced with custom-designed hardware and software which...
Apr 12, 2018 03:05 am ET
Novoheart Founder & CEO Dr. Ronald Li honored with 2017 Distinguished Alumnus Award by the University of Waterloo
VANCOUVER, British Columbia, April 12, 2018 (GLOBE NEWSWIRE) -- Novoheart (“Novoheart” or the “Company”) (TSXV:NVH) (FWB:3NH) is pleased to announce that Dr. Ronald Li, Founder and CEO of the Company, has been awarded with the 2017 Distinguished Alumnus Award...
Mar 29, 2018 03:05 am ET
Novoheart Files Patent Application on Disease Modeling Based on Landmark Research Conducted During Second Contract with Global Pharma Partner
Novoheart ("Novoheart" or the "Company") (TSX VENTURE: NVH)(FRANKFURT: 3NH) is pleased to announce that it has filed a patent application on the use of its proprietary MyHeart(TM) Platform of human bioengineered heart tissues to create disease models for neurological diseases in which afflicted patients suffer and often die from cardiac dysfunction. The IP, which is solely owned by Novoheart, was developed as part of the Company's successfully completed second contract with a Global Pharma partner.
Mar 29, 2018 03:03 am ET
Novoheart Files Patent Application on Disease Modeling Based on Landmark Research Conducted During Second Contract with Global Pharma Partner
Novoheart ("Novoheart" or the "Company") (TSX VENTURE:NVH)(FRANKFURT:3NH) is pleased to announce that it has filed a patent application on the use of its proprietary MyHeart™ Platform of human bioengineered heart tissues to create disease...
Mar 23, 2018 02:17 am ET
Novoheart Grants Options
Novoheart Holdings Inc. ("Novoheart" or the "Company") (TSX VENTURE:NVH)(FRANKFURT:3NH) announced today that it has granted incentive stock options to purchase an aggregate of 693,522 common shares of the Company (the "Options") to certain...
Mar 23, 2018 02:17 am ET
Novoheart Grants Options
Novoheart Holdings Inc. ("Novoheart" or the "Company") (TSX VENTURE: NVH)(FRANKFURT: 3NH) announced today that it has granted incentive stock options to purchase an aggregate of 693,522 common shares of the Company (the "Options") to certain directors and employees of the Company. The Options have an exercise price of $0.50 per common share. 520,000 of the Options expire on September 27, 2022 and vest 40% on September 27, 2018 and 30% on each of September 27, 2019 and 2020. The balance of the Options expire on February 23, 2023 and vest 40% on the first
Mar 14, 2018 03:05 am ET
Novoheart Opens New State-Of-The-Art Facilities at the Hong Kong Science Park
Novoheart ("Novoheart" or the "Company") (TSX VENTURE: NVH)(FRANKFURT: 3NH) is pleased to announce the opening of its brand new Hong Kong facility consisting of 5,300 ft2 of integrated laboratory and office space. Located in the Hong Kong Science Park, the laboratory is equipped with state-of-the-art facilities for stem cell production, tissue engineering and world-class research and development. The facility provides Novoheart with a new level of scalability enabling it to accommodate a significant number of additional revenue-generating commercial contracts and projects.
Mar 14, 2018 03:03 am ET
Novoheart Opens New State-Of-The-Art Facilities at the Hong Kong Science Park
Novoheart ("Novoheart" or the "Company") (TSX VENTURE:NVH)(FRANKFURT:3NH) is pleased to announce the opening of its brand new Hong Kong facility consisting of 5,300 ft² of integrated laboratory and office space. Located in the Hong Kong Science...
Mar 08, 2018 03:05 am ET
Novoheart's Landmark, Peer-Reviewed Study Published, Recognizing the Effectiveness of the World's First and Only Human Heart-in-a-Jar
(TSX VENTURE: NVH)(FRANKFURT: 3NH)
Mar 08, 2018 03:03 am ET
Novoheart's Landmark, Peer-Reviewed Study Published, Recognizing the Effectiveness of the World's First and Only Human Heart-in-a-Jar
(TSX VENTURE:NVH)(FRANKFURT:3NH)
"Human heart-in-a-jar" technology recognized by the scientific community for its unique ability to reproduce key physiological and pharmacological features of the native human heart,...
Feb 26, 2018 08:00 am ET
Novoheart Holdings Inc. Announces AGM Results, Receives Governmental Funding to Expand R&D Team, and Reports Second Quarter 2018 Financial Results
Novoheart Holdings Inc. ("Novoheart" or the "Company") (TSX VENTURE: NVH) today announced that it has been awarded two internship grants from the Innovation and Technology Commission (ITC) of Hong Kong to support the recruitment of local graduates. These have provided financial support towards the expansion of the R&D team in Hong Kong, allowing the Company to recruit and train top talent, in conjunction with its expansion into the brand new 5,300 sq ft facility in the Hong Kong Science Park, and thus accommodate additional commercial drug screening contracts. The two
Feb 26, 2018 07:58 am ET
Novoheart Holdings Inc. Announces AGM Results, Receives Governmental Funding to Expand R&D Team, and Reports Second Quarter 2018 Financial Results
Novoheart Holdings Inc. ("Novoheart" or the "Company") (TSX VENTURE:NVH) today announced that it has been awarded two internship grants from the Innovation and Technology Commission (ITC) of Hong Kong to support the recruitment of local graduates....
Feb 14, 2018 09:11 am ET
Novoheart Signs Agreement with Sumocor to Develop Novel Therapeutics for Heart Failure
Novoheart ("Novoheart" or the "Company") (TSX VENTURE:NVH), through its wholly owned US subsidiary, has entered into a commercial agreement with Sumocor LLC ("Sumocor"), a biotech company based in New York City that is focused on the development of...
Feb 14, 2018 09:10 am ET
Novoheart Signs Agreement with Sumocor to Develop Novel Therapeutics for Heart Failure
Novoheart ("Novoheart" or the "Company") (TSX VENTURE: NVH), through its wholly owned US subsidiary, has entered into a commercial agreement with Sumocor LLC ("Sumocor"), a biotech company based in New York City that is focused on the development of therapeutics for cardiovascular diseases. Pursuant to the agreement, Novoheart will test Sumocor's candidate therapeutics in three phases on Novoheart's MyHeart(TM) Platform of human bioengineered heart constructs, to provide thorough pre-clinical assessment of efficacy and cardiotoxicity in the context of the human
Jan 30, 2018 07:30 am ET
Novoheart Announces Successful Completion of Second Commercial Contract with Global Pharmaceutical Company
Novoheart ("Novoheart" or the "Company") (TSX VENTURE: NVH) is pleased to announce the successful completion of a second commercial contract with a major global pharma partner (Pharma). The second contract was initiated after a successful initial collaboration that validated the drug screening capabilities of Novoheart's proprietary MyHeart(TM) Platform.
Jan 30, 2018 07:27 am ET
Novoheart Announces Successful Completion of Second Commercial Contract with Global Pharmaceutical Company
Novoheart ("Novoheart" or the "Company") (TSX VENTURE:NVH) is pleased to announce the successful completion of a second commercial contract with a major global pharma partner (Pharma). The second contract was initiated after a successful...
Jan 16, 2018 07:30 am ET
Novoheart Files Patent Application on Three-Tier Drug Screening System After Successful Collaboration Contract with Global Pharma Company
Novoheart ("Novoheart" or the "Company") (TSX VENTURE: NVH) today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a three-tiered drug screening system with enhanced capability, sensitivity and accuracy for detecting pharmacological effects on heart contractility that cannot be achieved with conventional models. The application resulted from the Company's collaborative contract with a multi-national global pharma company ("Pharma"). The completion of this contract also led to a subsequent
Jan 16, 2018 07:28 am ET
Novoheart Files Patent Application on Three-Tier Drug Screening System After Successful Collaboration Contract with Global Pharma Company
Novoheart ("Novoheart" or the "Company") (TSX VENTURE:NVH) today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a three-tiered drug screening system with enhanced...
Dec 12, 2017 09:38 am ET
View from the C-Suite: Prof. Ronald Li, CEO of Novoheart Holdings, tells his company's story. Filmed on October 12, 2017
TORONTO, Dec. 12, 2017 /CNW/ -
Dec 11, 2017 08:00 am ET
Novoheart Profiled on CBC's Flagship News Program 'The National'
Novoheart ("Novoheart" or the "Company") (TSX VENTURE: NVH), a global stem cell biotechnology company, is pleased to announce that an in-depth feature on the company and its technology was broadcast on Friday, December 8th on CBC News, Canada's largest news broadcaster.
Dec 11, 2017 07:58 am ET
Novoheart Profiled on CBC's Flagship News Program 'The National'
Novoheart ("Novoheart" or the "Company") (TSX VENTURE:NVH), a global stem cell biotechnology company, is pleased to announce that an in-depth feature on the company and its technology was broadcast on Friday, December 8th on CBC News, Canada's...
Dec 05, 2017 07:30 am ET
Novoheart Publishes Landmark Study Demonstrating the Use of Machine Learning to Accelerate Drug Screening
Novoheart ("Novoheart" or the "Company") (TSX VENTURE: NVH), a global stem cell biotechnology company, is pleased to announce the publication of its study in Stem Cell Reports, the official journal of the International Society for Stem Cell Research. The study demonstrates how machine learning technology can be leveraged to efficiently analyze rich data content generated from drug screening studies using Novoheart's bioengineered human heart tissues.
Dec 05, 2017 07:28 am ET
Novoheart Publishes Landmark Study Demonstrating the Use of Machine Learning to Accelerate Drug Screening
Novoheart ("Novoheart" or the "Company") (TSX VENTURE:NVH), a global stem cell biotechnology company, is pleased to announce the publication of its study in Stem Cell Reports, the official journal of the International Society for Stem Cell Research....
Nov 30, 2017 07:30 am ET
Novoheart Files for Patent on Pioneering New Multi-organoid Bioreactor Platform
Novoheart ("Novoheart" or the "Company") (TSX VENTURE: NVH), a global stem cell biotechnology company, today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a versatile bioreactor platform that is used to culture, stimulate, and monitor the function of multiple engineered human-tissue organoids. The proprietary bioreactor system, which comprises hardware for organoid maintenance, manipulation and recording, together with customized software for seamless data processing and analysis, is designed to
Nov 30, 2017 07:28 am ET
Novoheart Files for Patent on Pioneering New Multi-organoid Bioreactor Platform
Novoheart ("Novoheart" or the "Company") (TSX VENTURE:NVH), a global stem cell biotechnology company, today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a versatile...
Nov 28, 2017 09:19 pm ET
Novoheart Holdings Inc. Reports First Quarter 2018 Financial Results
Novoheart Holdings Inc. ("Novoheart" or the "Company") (TSX VENTURE: NVH) today announced financial results for the three months ended September 30, 2017. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards (IFRS).
Nov 28, 2017 09:19 pm ET
Novoheart Holdings Inc. Reports First Quarter 2018 Financial Results
Novoheart Holdings Inc. ("Novoheart" or the "Company") (TSX VENTURE:NVH) today announced financial results for the three months ended September 30, 2017. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance...
Oct 25, 2017 08:06 pm ET
Novoheart Holdings Inc. Reports Fourth Quarter and Fiscal 2017 Financial Results
Novoheart Holdings Inc. (TSX VENTURE:NVH) ("Novoheart" or the " Company") today announced financial results for the three and twelve months ended June 30, 2017. Amounts, unless specified otherwise, are expressed in US dollars and are in...
Oct 25, 2017 08:06 pm ET
Novoheart Holdings Inc. Reports Fourth Quarter and Fiscal 2017 Financial Results
Novoheart Holdings Inc. (TSX VENTURE: NVH) ("Novoheart" or the " Company") today announced financial results for the three and twelve months ended June 30, 2017. Amounts, unless specified otherwise, are expressed in US dollars and are in accordance with International Financial Reporting Standards (IFRS).
Oct 25, 2017 08:00 am ET
Novoheart Strengthens North American Presence Opening New R&D Location at the World-class Cove Facility, UC Irvine, California
Novoheart ("Novoheart" or the "Company") (TSX VENTURE: NVH), a global stem cell biotechnology company, is pleased to announce that it has opened a new US location in The Cove at UC Irvine, California. The Cove is home to UCI Applied Innovation - a public-private endeavour to accelerate the commercialization of technology and other world-class discoveries at UCI - as well as a number of renowned VC firms, entrepreneurs and fast-growth technology organizations. It features 46,000 square feet of state-of-the-art technological facilities and collaborative office space and
Oct 25, 2017 07:58 am ET
Novoheart Strengthens North American Presence Opening New R&D Location at the World-class Cove Facility, UC Irvine, California
Novoheart ("Novoheart" or the "Company") (TSX VENTURE:NVH), a global stem cell biotechnology company, is pleased to announce that it has opened a new US location in The Cove at UC Irvine, California. The Cove is home to UCI Applied Innovation - a...
Oct 12, 2017 11:46 am ET
Novoheart Holdings Inc. Opens the Market
TORONTO, Oct. 12, 2017 /CNW/ - Professor Ronald Li, CEO & Scientific Co-Founder, Novoheart Holdings Inc., joined Rob Peterman, Vice-President, Global Business Development, TMX Group, to open the market. Novoheart is a global stem cell biotechnology company dedicated to human heart engineering with offices in Vancouver, British Columbia, the United States and Hong Kong. Novoheart Holdings Inc. commenced trading on TSX Venture Exchange on October 3, 2017.
Oct 02, 2017 05:38 pm ET
IIROC Trading Resumption - NVH
VANCOUVER, Oct. 2, 2017 /CNW/ - Trading resumes in:
Oct 02, 2017 04:28 pm ET
IIROC Trade Resumption - Novoheart Holdings Inc.
Vancouver, British Columbia--(Newsfile Corp. - October 2, 2017) - Trading resumes in:
Sep 28, 2017 10:39 am ET
Novoheart Holdings Inc. Completes Reverse Takeover Transaction
Novoheart Holdings Inc. ("Novoheart" or the "Company", formerly Woodrose Ventures Corporation ("Woodrose")), announces the completion of the previously announced acquisition (the "Transaction") of all of the shares of Novoheart Holdings Ltd. (the "Target"). The Transaction constituted a reverse takeover transaction of Woodrose pursuant to the TSX Venture Exchange (the "Exchange" or "TSXV") Policy 5.2 - Changes of Business and Reverse Takeovers.
Sep 28, 2017 10:39 am ET
Novoheart Holdings Inc. Completes Reverse Takeover Transaction
Novoheart Holdings Inc. ("Novoheart" or the "Company", formerly Woodrose Ventures Corporation ("Woodrose")), announces the completion of the previously announced acquisition (the "Transaction") of all of the shares of Novoheart Holdings Ltd. (the...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.